PHIO Insider Trading (Phio Pharmaceuticals)
Insider Ownership Percentage: 0.30%
Insider Buying (Last 12 Months): $9,780.00
Insider Selling (Last 12 Months): $0.00
Phio Pharmaceuticals Share Price & Price History
Current Price: $0.69
Price Change: ▲ Price Increase of +0.04 (6.13%)
As of 05/19/2022 05:00 PM ET
Last Century's Oil Boom Repeats Today With Lithium?
From Investing Trends | Ad
The budding lithium industry looks similar to early days of the oil boom. In fact, lithium has been called the "new oil." As internal combustion engines give way to lithium-filled electric vehicle batteries, demand for the metal is skyrocketing. The U.S. is desperate for more domestic sources of lithium, and geologists are pointing to Nevada.
See Why Nevada Lithium Opportunity Looks Promising
Phio Pharmaceuticals Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 8/16/2021 | Gerrit Dispersyn | CEO | Buy | 6,000 | $1.63 | $9,780.00 | |  |
| 3/3/2021 | Gerrit Dispersyn | CEO | Buy | 2,500 | $3.03 | $7,575.00 | | |
| 3/3/2021 | Robert L. Ferrara | Director | Buy | 682 | $3.15 | $2,148.30 | | |
| 8/19/2020 | Gerrit Dispersyn | CEO | Buy | 2,000 | $2.50 | $5,000.00 | | |
Warning: The Last Value Play Gone After August?
From Oxford Club | Ad
In this market...There's ONE STOCK (priced at just under $2) that could be $20 and STILL be a bargain. It brought in more income – including equity sales - in the last 12 months than Disney, Square or Tesla.
But a key announcement in August could send this stock rocketing skyward
Get the Details Now.
Phio Pharmaceuticals Institutional Trading History
| Reporting Date | Hedge Fund | Shares Held | Market Value | % of Portfolio | Quarterly Change in Shares | Ownership in Company | Details |
|---|
| 5/13/2022 | Renaissance Technologies LLC | 41,500 | $37K | 0.0% | +310.9% | 0.304% |  |
| 5/13/2022 | Vanguard Group Inc. | 304,119 | $0.27M | 0.0% | +6.8% | 2.226% | |
| 5/13/2022 | Cetera Investment Advisers | 90,000 | $80K | 0.0% | +125.0% | 0.659% | |
| 2/15/2022 | Millennium Management LLC | 45,397 | $45K | 0.0% | -63.0% | 0.335% | |
| 11/16/2021 | Cetera Investment Advisers | 30,000 | $61K | 0.0% | N/A | 0.222% | |
| 11/16/2021 | Two Sigma Advisers LP | 153,100 | $0.31M | 0.0% | +165.8% | 1.131% | |
| 11/16/2021 | Millennium Management LLC | 122,693 | $0.25M | 0.0% | +1,122.7% | 0.907% | |
| 11/12/2021 | Geode Capital Management LLC | 107,192 | $0.22M | 0.0% | +22.5% | 0.792% | |
| 11/9/2021 | BlackRock Inc. | 35,592 | $72K | 0.0% | -17.8% | 0.263% | |
| 9/17/2021 | Virtu Financial LLC | 27,110 | $61K | 0.0% | +74.7% | 0.200% | |
| 8/16/2021 | Goldman Sachs Group Inc. | 19,002 | $43K | 0.0% | N/A | 0.140% | |
| 8/13/2021 | Vanguard Group Inc. | 276,561 | $0.63M | 0.0% | +125.4% | 2.043% | |
| 8/12/2021 | Dimensional Fund Advisors LP | 23,960 | $54K | 0.0% | -31.2% | 0.177% | |
| 5/19/2021 | Virtu Financial LLC | 15,522 | $42K | 0.0% | N/A | 0.115% | |
| 5/14/2021 | Dimensional Fund Advisors LP | 34,808 | $93K | 0.0% | +38.3% | 0.257% | |
| 5/12/2021 | Geode Capital Management LLC | 87,501 | $0.23M | 0.0% | +330.6% | 0.647% | |
| 5/10/2021 | GSA Capital Partners LLP | 132,333 | $0.36M | 0.1% | +30.5% | 0.978% | |
| 3/26/2021 | Susquehanna International Group LLP | 12,058 | $32K | 0.0% | N/A | 0.085% | |
| 3/8/2021 | Dimensional Fund Advisors LP | 25,177 | $68K | 0.0% | N/A | 0.178% | |
| 2/25/2021 | Dimensional Fund Advisors LP | 25,177 | $68K | 0.0% | N/A | 0.178% | |
| 2/4/2021 | GSA Capital Partners LLP | 101,401 | $0.27M | 0.0% | +376.6% | 1.754% | |
| 12/11/2020 | Virtu Financial LLC | 35,929 | $77K | 0.0% | N/A | 0.622% | |
| 11/6/2020 | GSA Capital Partners LLP | 21,278 | $46K | 0.0% | N/A | 0.368% | |
| 7/16/2020 | Wedbush Securities Inc. | 33,374 | $73K | 0.0% | N/A | 0.577% | |
| 5/15/2020 | Sabby Management LLC | 255,194 | $0.45M | 0.2% | N/A | 8.901% | |
| 5/12/2020 | JPMorgan Chase & Co. | 21,681 | $38K | 0.0% | N/A | 0.755% | |
| 2/14/2020 | UBS Group AG | 45,409 | $0.43M | 0.0% | +43.3% | 6.997% | |
| 2/13/2020 | Renaissance Technologies LLC | 333,890 | $57K | 0.0% | +585.9% | 51.447% | |
| 1/28/2020 | SG Americas Securities LLC | 792,374 | $0.14M | 0.0% | +12.3% | 121.904% | |
| 11/4/2019 | SG Americas Securities LLC | 705,353 | $0.19M | 0.0% | +16.9% | 2.756% | |
| 8/16/2019 | CVI Holdings LLC | 406,358 | $0.15M | 0.1% | -32.8% | 1.701% | |
| 8/14/2019 | Citadel Advisors LLC | 85,621 | $33K | 0.0% | +148.9% | 0.358% | |
| 6/30/2019 | SG Americas Securities LLC | 603,528 | $0.23M | 0.0% | +163.8% | 2.526% | |
| 4/29/2019 | SG Americas Securities LLC | 228,825 | $0.10M | 0.0% | +39.8% | 1.026% | |
| 4/12/2019 | Virtu Financial LLC | 238,544 | $0.11M | 0.0% | N/A | 1.070% | |
Data available starting January 2016
Phio Pharmaceuticals Corp. develops immuno-oncology therapeutics in the United States. It offers INTASYL therapeutic platform focuses on targeting tumor and immune cells by regulating genes of the immune system. The company develops PH-762 that activates immune cells to recognize and kill cancer cells by reducing the expression of the checkpoint protein PD-1 for immunotherapy in adoptive cell transfer (ACT); PH-894 that silences the epigenetic protein BRD4, which is an intracellular regulator of gene expression for use in ACT; and PH-804 that targets the suppressive immune receptor TIGIT, which is a checkpoint protein present on T cells and natural killer cells for use in ACT. It has collaborations with AgonOx Inc. on clinical development of novel T cell-based cancer immunotherapies. The company was formerly known as RXi Pharmaceuticals Corporation and changed its name to Phio Pharmaceuticals Corp. in November 2018. Phio Pharmaceuticals Corp. was incorporated in 2011 and is headquartered in Marlborough, Massachusetts.
Read More on Phio Pharmaceuticals
Volume
253,601 shs
Average Volume
759,851 shs
Market Capitalization
$9.45 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
1.68
Who are the company insiders with the largest holdings of Phio Pharmaceuticals?
Who are the major institutional investors of Phio Pharmaceuticals?
Which institutional investors are buying Phio Pharmaceuticals stock?
During the previous quarter, PHIO stock was purchased by institutional investors including:
- Cetera Investment Advisers
- Renaissance Technologies LLC
- Vanguard Group Inc.
During the previous year, these company insiders have bought Phio Pharmaceuticals stock:
- Gerrit Dispersyn (CEO)
- Robert L Ferrara (Director)
Learn More investors buying Phio Pharmaceuticals stock.
